Products - Chronic liver disease | Topic | NICE

Showing 6 products

Date | Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter
Status: In developmentRemove ‘Status: In development’ filter

Semaglutide for treating moderate to advanced liver fibrosis (without cirrhosis) caused by metabolic dysfunction-associated steatohepatitis [ID6458]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
7 January 2027
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Status:
In development
Programme:
NICE guideline
Expected publication date:
27 July 2027
Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC